Correction to Levels of Polycyclic Aromatic Hydrocarbons in Maternal Serum and Risk of Neural Tube Defects in Offspring.

In Table (Page 592) of the published paper, the columns of the lower and upper limits of 95% confidence of the adjusted OR for the total NTDs should interchange with each other. For example, “1.98 (3.86–1.02)” should be “1.98 (1.02–3.86)”. The columns of the adjusted OR and the lower limit of 95% confidence for anencephaly should interchange with each other. For example, “0.74 (1.93–5.01)” should be “1.93 (0.74–5.01)”. A corrected Table is included below and the data requiring revision are marked in bold.

Table 3

Risks of Neural Tube Defects (NTDs) in Association with Levels of Polycyclic Aromatic Hydrocarbons (PAHs) above the Median Concentration in Maternal Serum of Controls in Shanxi Province, China, 2010–2013

			total NTDs		anencephaly		spina bifida
PAHsa		median (IQR)b	crude ORc (95% CI)	adjusted ORc,d(95% CI)	crude ORc (95% CI)	adjusted ORc,d(95% CI)	crude ORc (95% CI)	adjusted ORc,d (95% CI)
L-PAHs	ANY	140 (19.8–368)	1.82 (1.08–3.07) *	1.98 (1.02–3.86) *	1.17 (0.58–2.35)	1.93 (0.74–5.01)	1.60 (0.86–2.95)	2.16 (0.95–4.90)
	ACE	194 (58.5–416)	4.25 (2.37–7.62) ***	4.50 (2.13–9.51) ***	2.37 (1.12–5.04) *	4.38 (1.44–13.28) **	3.70 (1.83–7.47) ***	3.84 (1.57–9.40) **
	FLE	588 (204–1333)	2.50 (1.46–4.29) **	2.84 (1.44–5.62) **	2.12 (1.01–4.45) *	3.14 (1.13–8.74) *	1.95 (1.04–3.65) *	2.15 (0.97–4.79)
	PHE	1051 (404–2396)	2.40 (1.41–4.10) **	2.99 (1.51–5.91) **	1.37 (0.68–2.77)	2.25 (0.86–5.87)	1.89 (1.01–3.54) *	2.01 (0.91–4.45)
	ANT	95.4 (45.1–194)	7.87 (4.00–15.5) ***	8.53 (3.77–19.29) ***	4.87 (2.01–11.8) ***	6.45 (1.96–21.21) **	7.89 (3.34–18.7) ***	7.91 (2.83–22.11) ***
	FLU	199 (42.8–462)	2.70 (1.57–4.64) ***	3.36 (1.68–6.71) ***	1.67 (0.82–3.39)	3.48 (1.25–9.64) *	2.59 (1.36–4.95) **	2.25 (1.00–5.05)
	RET	378 (109–787)	2.20 (1.30–3.73) **	2.30 (1.16–4.53) *	1.29 (0.64–2.59)	1.44 (0.57–3.66)	2.09 (1.11–3.94) *	1.78 (0.79–4.04)
H-PAHs	PYR	289 (120–658)	2.40 (1.41–4.10) **	2.31 (1.16–4.60) *	1.78 (0.87–3.65)	3.10 (1.09–8.88) *	2.16 (1.15–4.08) *	2.11 (0.93–4.78)
	BAA	92.4 (30.1–190)	3.23 (1.86–5.63) ***	3.17 (1.56–6.46) **	2.42 (1.16–5.08) *	3.60 (1.28–10.11) *	4.22 (2.09–8.53) ***	4.41 (1.76–11.05) **
	CHR	106 (24.3–285)	2.82 (1.64–4.86) ***	3.08 (1.51–6.26) **	1.72 (0.84–3.53)	2.93 (1.07–8.01) *	2.62 (1.36–5.05) **	2.84 (1.19–6.77) *
	BBF	71.2 (0–143)	2.11 (1.25–3.58) **	2.40 (1.21–4.75) *	1.72 (0.85–3.50)	3.44 (1.23–9.62) *	2.31 (1.23–4.35) **	2.22 (0.98–5.00)
	BKF	19.8 (0–69.0)	1.97 (1.16–3.32) *	2.56 (1.28–5.11) **	1.67 (0.82–3.39)	3.36 (1.20–9.39) *	2.08 (1.11–3.90) *	2.65 (1.15–6.09) *
	BAP	36.4 (7.90–147)	2.48 (1.45–4.24) ***	2.46 (1.22–4.93) *	3.15 (1.46–6.81) **	1.79 (0.68–4.70)	3.09 (1.60–5.95) ***	2.83 (1.18–6.76) *
	ΣL-PAHs	2851 (1307–6683)	2.61 (1.52–4.49) ***	2.91 (1.45–5.83) ***	1.72 (0.84–3.53)	2.59 (0.95–7.07)	2.09 (1.11–3.94) *	2.00 (0.89–4.49)
	∑H-PAHs	805 (420–1514)	4.65 (2.57–8.40) ***	5.89 (2.72–12.75) **	2.76 (1.28–5.96) **	4.42 (1.48–13.19) **	4.69 (2.24–9.81) ***	4.31 (1.71–10.88) **
	∑PAHs	3656 (1805–8294)	2.95 (1.71–5.09) ***	3.24 (1.55–6.80) **	2.20 (1.05–4.60) *	3.76 (1.31–10.77) *	2.16 (1.15–4.08) *	2.29 (1.01–5.17) *

OR, odds ratio; IQR, interquartile range; * p < 0.05, ** p < 0.01, and *** p < 0.001.

The abbreviations of individual PAHs are acenaphthylene (ACY), acenaphthene (ACE), fluorene (FLE), phenanthrene (PHE), anthracene (ANT), fluoranthene (FLU), retene (RET), pyrene (PYR), benz[a]anthracene (BAA), chrysene (CHR), benzo[b]fluoranthene (BBF), benzo[k]fluoranthene (BKF), benzo[a]pyrene (BAP). ∑L-PAHs is the sum of ANY, ACE, FLE, PHE, ANT, FLU, and RET; ∑H-PAHs of PYR, BAA, CHR, BBF, BKF and BAP; ∑PAHs of ∑L-PAHs and ∑H-PAHs.

Statistical results of all subjects.

Calculated by using binary logistic regression.

Adjust for maternal general characteristics and exposure, including BMI, parity, fever of flu during early pregnancy, and active or passive smoking and drinking.